Excellent discussions on the potential applications of AI-driven tools in management of patients with PF- much more to be done to change the landscape to meet criteria for meaningful endpoint! #curePF

…and a whole lot of good cheer with friends from all around the globe 🌏!!! #LearningFromTheBest #ATS2024 #MTWC

Moments like this makes it worth coming to #ATS2024

Now please meet SUPER #ValerieQuinn, REMAP-ILD project manager 🤩 Valerie rocks BIG TIME, you have no idea! Thanks, Valerie for your dedication to #REMAPILD! I am so happy to meet you in person for the first time! Ping Gisli Jenkins Tejaswini Kulkarni Kerri Johannson MD MPH

Prof. Athol Wells presents elegant data from a recent multinational Delphi consensus that: • Progression of ILD is progression irrespective of time since diagnosis •“despite usual management” should be included in PPF definition Important for future PPF guidelines. #ATS2024

A great discussion on the methodology of these upcoming guidelines and key take away points on management of patients with SARD-ILD - #curePF #CHEST_ILDTx CHEST ATS Clinical Problems Assembly Pulmonary Fibrosis Foundation

Telomere length testing is a readily available clinical test for precision management of ILD. We describe the clinical impact of TL testing in ILD clinic including impact on pharmacologic management and genetic testing CHEST® Journal journal.chestnet.org/article/S0012-…

In clinical practice,there are often questions about approach to positive antibodies in the absence clinical signs of SARD. This study shows that IPF disease course and response to Pirfenidone did not differ by autoantibody status #CurePF Chad Newton

To commemorate Pulmonary Fibrosis Awareness Month, we will be sharing brilliant Pulmonary Fibrosis research from Thorax over the last year #CurePF This paper highlights the innovative REMAP-ILD concept for drug development in fibrotic ILDs Leticia Kawano-Dourado Gisli Jenkins

Wow! Boehringer-Ingelheim announces that Nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study - a decade after the first positive phase III trials for IPF. Cannot wait to see the full results but this EXCITING !!! #CureIPF boehringer-ingelheim.com/us/topline-res…

Join us for journal club Thursday, October 3rd, 10 am EST on "Microscopic Small Airway Abnormalities Identified in Early Idiopathic Pulmonary Fibrosis In Vivo Using Endobronchial Optical Coherence Tomography" Register here: thoracic.zoom.us/meeting/regist…

Excellent discussion on early initiation of anti-fibrotic therapy in Non-IPF fibrotic lung disease, led by Tejaswini Kulkarni and Dr. Danoff. Should our primary emphasis be on enhancing QoL? Active involvement of patients in decision-making processes is key! #CHEST2024 #CHESTTrainees

#ICLAF2024 kicking off with patient experience session and looking forward to 5 days of advances towards #curePF

Excellent panel discussing disparities and environmental exposures in ILDs - #ICLAF2024 #CurePF

Clinical Trials whirlwind at #ICLAF2024 Many early phase RCTs underway 💊 Some optimism in current phase III’s 🤩 Innovative approaches will accelerate discovery REMAP-ILD 💪🫁 Tejaswini Kulkarni Ian Glaspole

Lessons learnt, cautious optimism and moving forward in clinical trials in ILD - #ICLAF2024

Great talk at #ICLAF2024 by Prof Kulkarni on phase 3 clinical trials in Pulmonary Fibrosis - provides insight on failure - hope for success 👏🏼👏🏼👏🏼Tejaswini Kulkarni 👏🏼👏🏼🙏🏼

Our Annals of the ATS paper exploring factors associated with persistence of antifibrotic therapies among patients with IPF enrolled in Pulmonary Fibrosis Foundation registry is now in press; underscores the importance of addressing mental health. #curePF Amy Hajari Case UAB Pulmonary

#CHEST2024 Recap: Experts discussed how to evaluate and manage clinical worsening in patients with PH-ILD. Read more in CHEST Daily News: hubs.la/Q02VyD6P0

This is a wonderful recognition for CRISPR! Congrats to all the innovators for all these groundbreaking inventions.